BGPT: Which specific enzyme-moonlighting mechanisms have the strongest cross-species and cross-cell-type causal validation, and which rely mostly on single-context localization or inhibitor studies? Previous Question: Paper Review: The Non-canonical Role of Metabolic Enzymes in Immune Cells and Its Impact on Diseases

Explore by Goal

Quick Answer Copied

Across the supplied records, PKM2, GAPDH, and GLS show the strongest cross-context causal validation (multiple cell types, human and mouse models, genetic plus pharmacologic perturbation), while TKT, ASNS, LDH-A, ENO-1, and SCD remain single-context or inhibitor-dependent claims ().

Long Answer

Tier 1 — cross-species + cross-cell-type causal validation (strongest)

PKM2 is validated in murine macrophages (AnxA5 binding, Y105 dephosphorylation, tetramer promotion; HFD NASH in vivo, n=9/group) ; in NSCLC via the CIP2A–PKM2–PP2A axis with xenografts (n=6/group) and 98 patient tissues ; and in RCC via the TKT–PKM2 interaction with co-IP, knockdown/rescue, and TCGA survival data (n=541 tumors) .

GAPDH spans T cells (IFN-γ mRNA repression), macrophages (GAIT complex), and now heme chaperoning — the FLVCR1b→GAPDH→sGCβ/IDO1 pathway is validated in human HEK293T/HeLa cells plus isolated mouse mitochondria with rescue experiments .

GLS is causally validated across MEFs, 12 breast cancer lines (c-Jun/GLS R=0.85; BPTES IC50 shifts 1.8→12 mM with SP600125), TCGA (959 samples), murine brain CD11b+ cells (JHU-083), transgenic Nes-GAC mice, and human leukemia cell lines (ASNase cytotoxicity tracks glutaminase activity across 11 lines) .

Tier 2 — single-context or inhibitor-dependent claims

TKT: only RCC contexts (786-O/ACHN, xenografts, TCGA RCC) — no cross-tissue validation . ASNS: leukemia cell lines only, in vitro, no in vivo . ENO-1, LDH-A, SCD, PDH/PDK, citrate synthase, SDH/FH: reported in the review as single-cell-type or pharmacologic-inhibitor-based findings without cross-species genetic rescue . HK NLRP3 sensing is mechanistically defined but primarily macrophage-restricted in the review.

Confidence: moderate-high for Tier 1 assignments (records include knockdown/rescue, in vivo, and human cohort data); lower for Tier 2 where the review's narrative citations cannot be independently quality-weighted. Missing: no record provides human in vivo validation for PKM2 macrophage mechanism, and no negative-result or replication studies are available for any claim.

Feedback:

Updated: September 27, 2026

BGPT Paper Review

Study Novelty

80%

Synthesizes cross-species validation hierarchies across moonlighting enzymes — an underexplored comparative-causality framing not standard in the individual papers.

Scientific Quality

80%

Claims are grounded in quantitative records with replicates; review-derived Tier 2 items are weaker and narrative-based, lowering confidence for those entries.

Study Generality

70%

Ranking framework generalizes to other moonlighting enzymes but is constrained to the 6 enzymes with quantitative records supplied.

Study Usefulness

80%

Directly prioritizes which moonlighting mechanisms merit drug-target investment vs which need replication before therapeutic pursuit.

Study Reproducibility

70%

Tier 1 assignments trace to reported n, effect sizes, and model systems; Tier 2 relies on a narrative review lacking systematic criteria.

Explanatory Depth

80%

Mechanistic chains (e.g., PKM2 Y105→tetramer→HIF-1α; GLS→c-Jun→BPTES sensitivity) are decomposed to residue and pathway level from the records.

Top Data Sources Export MCP

1. This review summarizes noncanonical roles of glycolytic and other metabolic enzymes in immune cell activation and differentiation, highlighting how metabolism-linked enzymes regulate immune responses beyond their traditional catalytic functions and discussing implications for autoimmunity, infection, cancer, and transplantation. [2020]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

2. This review discusses the regulation of glutaminase activity and glutamine metabolism, highlighting the distinct roles of liver-type and kidney-type glutaminases in various physiological and pathological states. [1995]

8QualityResults Limitations Context Blindspots Methods

↗ Paper Review ↗ Full Paper

3. c-Jun, activated via JNK signaling downstream of Rho GTPases, transcriptionally upregulates GLS to boost glutamine metabolism and creates a glutaminase-dependent vulnerability in breast cancer cells that can be exploited by GLS inhibitors. [2016]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

4. This study investigates how circadian clock gene expression regulates glutaminase activity and cancer cell growth, revealing that inhibiting glutaminase during its peak expression may offer a novel therapeutic target for liver cancer treatment. [2014]

8QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

5. The study reveals that asparagine synthetase (ASNS) exhibits glutaminase activity that promotes glutamine metabolism in leukemia cells, supporting TCA cycling, nucleotide synthesis, and resistance to glutaminase inhibitors, thereby highlighting ASNS as a potential co-target with GLS inhibitors for therapy. [2025]

8QualityResults Limitations Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

Key Insight

Moonlighting evidence quality correlates with the availability of a clean orthologous genetic perturbation — enzymes with catalytic-dead or binding-site mutants (PKM2 Y105E, GLS BPTES) accumulate cross-species validation faster than those relying on metabolic-flux inhibitors alone.

Keep Exploring

What fraction of published moonlighting claims survive catalytic-dead mutant rescue in vivo across species?

Does PKM2 tetramerization state predict inflammatory outcome in human patient macrophages, not just mouse models?

Potential Experiments

Catalytic-dead PKM2 knock-in in macrophage-specific conditional mice: if NLRP3/HIF-1α phenotypes persist with dead enzyme, moonlighting is separable from flux — a direct cross-species test humanized in NSCLC xenografts.

Cross-species GLS inhibitor sensitivity panel (mouse, human, rat primary macrophages + T cells) with matched isotope-tracing flux readouts to quantify how much GLS moonlighting effect survives flux-matched controls.

Science Art

Which specific enzyme-moonlighting mechanisms have the strongest cross-species and cross-cell-type causal validation, and which rely mostly on single-context localization or inhibitor studies?

Previous Question: Paper Review: The Non-canonical Role of Metabolic Enzymes in Immune Cells and Its Impact on Diseases Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may over-weight mechanistic-molecular evidence over ecological/system-level validation, underrepresenting physiological context-dependence.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Answer Copied

Long Answer

Tier 1 — cross-species + cross-cell-type causal validation (strongest)

Tier 2 — single-context or inhibitor-dependent claims

BGPT Paper Review

Study Novelty

Synthesizes cross-species validation hierarchies across moonlighting enzymes — an underexplored comparative-causality framing not standard in the individual papers.

Scientific Quality

Claims are grounded in quantitative records with replicates; review-derived Tier 2 items are weaker and narrative-based, lowering confidence for those entries.

Study Generality

Ranking framework generalizes to other moonlighting enzymes but is constrained to the 6 enzymes with quantitative records supplied.

Study Usefulness

Directly prioritizes which moonlighting mechanisms merit drug-target investment vs which need replication before therapeutic pursuit.

Study Reproducibility

Tier 1 assignments trace to reported n, effect sizes, and model systems; Tier 2 relies on a narrative review lacking systematic criteria.

Explanatory Depth

Mechanistic chains (e.g., PKM2 Y105→tetramer→HIF-1α; GLS→c-Jun→BPTES sensitivity) are decomposed to residue and pathway level from the records.

Top Data Sources ExportMCP

2. This review discusses the regulation of glutaminase activity and glutamine metabolism, highlighting the distinct roles of liver-type and kidney-type glutaminases in various physiological and pathological states. [1995]

3. c-Jun, activated via JNK signaling downstream of Rho GTPases, transcriptionally upregulates GLS to boost glutamine metabolism and creates a glutaminase-dependent vulnerability in breast cancer cells that can be exploited by GLS inhibitors. [2016]

4. This study investigates how circadian clock gene expression regulates glutaminase activity and cancer cell growth, revealing that inhibiting glutaminase during its peak expression may offer a novel therapeutic target for liver cancer treatment. [2014]

6. The study demonstrates that JHU-083, a prodrug of the glutaminase inhibitor DON, effectively blocks glutaminase activity in brain CD11b+ cells and alleviates depression-associated behaviors in mice subjected to chronic social defeat stress. [2018]

7. This study investigates the differential effects of the glutamine antagonist AT-125 on rat renal glutaminase activities, demonstrating its selective inhibition of y-glutamyltranspeptidase without affecting phosphate-dependent glutaminase activity. [1981]

10. This study identifies two human glutaminase loci on chromosomes 2 and 12, revealing distinct tissue-specific expression patterns for the K- and L-type isoforms of the enzyme, which differ from previously established models based on rat studies. [2000]

12. CIP2A binds PKM2 to promote PKM2 tetramer formation and mitochondrial localization, boosting oxidative phosphorylation and Bcl2 signaling in NSCLC, with CIP2A inhibitors synergizing with glycolysis blockade to suppress tumor growth. [2024]

13. This study demonstrates that overexpression of glutaminase C in the brain of transgenic mice leads to significant learning deficits, synaptic dysfunctions, and neuroinflammation, providing insights into the potential role of glutaminase in neurological disorders. [2017]

14. This study investigates the metabolic changes induced by the expression of glutaminase-2 (GLS2) in glioblastoma cells, revealing its role in regulating pyruvate dehydrogenase activity and linking glutamine and glucose metabolism. [2025]

15. This study presents a novel staining method for detecting glutaminase activity in polyacrylamide gels and cellulose acetate strips, demonstrating its specificity and sensitivity for enzyme assays. [1973]

16. This study identifies the nuclear receptor PPARγ as a novel binding partner of glutaminases KGA and GAC, revealing their role in transcriptional regulation by sequestering PPARγ from its responsive element, thereby decreasing its activity. [2018]

17. This study demonstrates that glutaminase activity is crucial for the cytotoxic efficacy of l-asparaginases in treating acute lymphoblastic leukemia (ALL), as evidenced by the comparative analysis of various ASNase isoforms on human leukemia cell lines. [2015]

19. This study investigates the distribution of glutaminase-like immunoreactivity in the organ of Corti of guinea pigs, revealing its presence in auditory nerve dendrites and efferent nerve endings at outer hair cells, with implications for understanding cochlear function. [1985]

21. This study reclassifies G6PD Chicago and Cornell as the same variant and reports a new variant, G6PD Pea Ridge, that closely resembles Chicago but differs in electrophoretic mobility and certain kinetic parameters, highlighting heterogeneity among G6PD variants. [1980]

Ask a Follow-Up

Key Insight

Moonlighting evidence quality correlates with the availability of a clean orthologous genetic perturbation — enzymes with catalytic-dead or binding-site mutants (PKM2 Y105E, GLS BPTES) accumulate cross-species validation faster than those relying on metabolic-flux inhibitors alone.

Keep Exploring

What fraction of published moonlighting claims survive catalytic-dead mutant rescue in vivo across species?

Does PKM2 tetramerization state predict inflammatory outcome in human patient macrophages, not just mouse models?

Potential Experiments

Catalytic-dead PKM2 knock-in in macrophage-specific conditional mice: if NLRP3/HIF-1α phenotypes persist with dead enzyme, moonlighting is separable from flux — a direct cross-species test humanized in NSCLC xenografts.

Cross-species GLS inhibitor sensitivity panel (mouse, human, rat primary macrophages + T cells) with matched isotope-tracing flux readouts to quantify how much GLS moonlighting effect survives flux-matched controls.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may over-weight mechanistic-molecular evidence over ecological/system-level validation, underrepresenting physiological context-dependence.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP